Drug discovery

Elsevier and Iktos Partner to Deliver an AI-Driven Synthetic Chemistry Platform for Drug Discovery

Retrieved on: 
Tuesday, March 5, 2024

Combining the world's largest chemistry database, Reaxys from Elsevier, with cutting-edge AI from Iktos, the advanced platform will enable pharmaceutical companies to identify preclinical drug candidates faster

Key Points: 
  • The partnership will strengthen Elsevier's flagship chemistry solution, Reaxys , by combining the company's high-quality chemistry data with synthetic planning AI technologies developed by Iktos to accelerate chemistry research for pharmaceutical companies.
  • We are delighted to partner with Iktos to bring the valued industry insights that Reaxys offers powered by artificial intelligence, which will help reshape the landscape of small molecule discovery."
  • Yann Gaston-Mathé, CEO, Iktos said: "Data is the foundation of AI, and we are very excited to partner with Elsevier.
  • The new predictive retrosynthesis and synthetic accessibility tools are based on Iktos' proprietary retrosynthetic technology and trained on Reaxys' reaction database.

Pattern to Attend NVIDIA’s GTC 2024 Conference

Retrieved on: 
Monday, March 11, 2024

REDMOND, Wash., March 11, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will attend NVIDIA’s GTC 2024 Conference.

Key Points: 
  • REDMOND, Wash., March 11, 2024 (GLOBE NEWSWIRE) -- Pattern Computer®, Inc. (“Pattern” or “the Company”) today announced that Mark R. Anderson, Chairman and CEO, will attend NVIDIA’s GTC 2024 Conference.
  • During the conference, Pattern will conduct one-on-one meetings with investors and potential partners, showcasing the Company’s business and clinical development strategy, recent corporate achievements, and anticipated milestones.
  • To schedule a meeting with Pattern, please contact Pattern’s Executive Vice President of Special Projects, Denyse Hudson, at [email protected] .
  • Mr. Anderson commented, “Pattern uses proprietary pattern discovery techniques to perform high-dimensional data analytics in any field with significant data complexity.

CytomX Therapeutics Reports 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, March 11, 2024

SOUTH SAN FRANCISCO, Calif., March 11, 2024 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated, localized biologics, today reported full year 2023 financial results and provided a business update.

Key Points: 
  • Throughout 2023, CytomX made substantial progress across all research partnerships including the commencement of programs under its new alliances with Regeneron and Moderna.
  • In 2023, CytomX remained focused on controlling costs and efficiently allocating capital towards its lead pipeline programs.
  • General and administrative expenses in the fourth quarter of 2023 were $7.8 million compared to $10.1 million in the corresponding period in 2022.
  • CytomX management will host a conference call and simultaneous webcast today at 5 p.m. EDT (2 p.m. PDT) to discuss the financial results and provide a business update.

Recursion Announces Plans to Open New Office in London

Retrieved on: 
Monday, March 11, 2024

LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood.

Key Points: 
  • LONDON, March 11, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced plans to open a new office in London’s vibrant King’s Cross neighborhood.
  • "London stood out as an ideal location given its brilliant and interdisciplinary talent across the fields of technology, biology and chemistry.
  • Recursion’s new London office will serve as an extension of both Recursion and Valence Labs’ teams.
  • To launch recruiting efforts for the new site, Recursion has opened multiple new roles across technology and biology functions with immediate plans to hire the first 20 people to be based out of the new London office.

Orion Biotechnology Presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston

Retrieved on: 
Thursday, March 7, 2024

Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston on March 7th.

Key Points: 
  • Ottawa, Canada, March 06, 2024 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd. (Orion), a drug discovery and development company unlocking the therapeutic potential of previously undruggable G Protein-Coupled Receptors (GPCRs), today announced that it will be presenting at the 3rd GPCR-Targeted Drug Discovery Summit in Boston on March 7th.
  • Dr. Oliver Hartley, Orion’s Vice President of Drug Discovery, will be presenting Orion’s PROcisionXTM discovery platform and its ability to unlock peptide and protein GPCRs with industry leading efficiency.
  • Additionally, Dr. Hartley will provide an update on Orion’s portfolio of GPCR-targeted therapeutics, including the recent discovery of both antagonists and agonists against GIPR and CXCR6.
  • Commenting on his presentation, Dr. Hartley said “I’m pleased to be presenting Orion’s technology and its ability to rapidly generate innovative therapies for metabolic and immunological diseases.

Oxford BioTherapeutics Announces Launch of Enhanced Discovery Platform, OGAP®-Verify, at World ADC Conference 2024

Retrieved on: 
Thursday, March 7, 2024

“I am delighted to announce major technological advances with the launch of OBT’s OGAP-Verify target discovery platform.

Key Points: 
  • “I am delighted to announce major technological advances with the launch of OBT’s OGAP-Verify target discovery platform.
  • OGAP-verify is now more sensitive than IHC and allows for enhanced sensitivity with improved target selection, solving some of the challenges in antibody specificity,” said Christian Rohlff, CEO, Oxford BioTherapeutics.
  • “OBT is dedicated to discovering and validating the next generation of ADC targets for safe and effective medicines.
  • OBT is a Partner of the Annual World ADC Conference 2024 in London, UK.

Enterome Announces Upcoming Presentation on OncoMimics™ Approach to Cancer Immunotherapy at the AACR Annual Meeting 2024

Retrieved on: 
Wednesday, March 6, 2024

The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.

Key Points: 
  • The poster will be presented by Dr. Vincent Panneton, Postdoctoral Associate in Pharmacology at the Ludwig Collaborative Laboratory led by Dr. Taha Merghoub and Dr. Jedd Wolchok at Weill Cornell Medicine.
  • “We are pleased to announce the presentation of these promising preclinical data which provide novel insights into the design of OncoMimics™ peptides for both neoantigens and tumor-associated antigens.
  • These results serve as an early validation of our approach to novel cancer immunotherapies,” said Laurent Chêne, Head of Drug Discovery at Enterome.
  • The abstract will be published in an online supplement to Cancer Research, the official journal of the American Association for Cancer Research, on March 22nd, and the poster will be available on Enterome’s website after the AACR Meeting.

Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors

Retrieved on: 
Monday, March 4, 2024

Dr. Palani added, “Acrivon is an entirely science-based company and its AP3 platform is a ground-breaking approach which is broadly applicable across drug discovery and development with significant unrealized potential -- not only in oncology but also in other areas including autoimmune and metabolic disorders, as dysregulated signaling ultimately underlies all diseases. The company currently is focused on oncology with a highly differentiated profile in this space. I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

Key Points: 
  • “Santhosh previously served as an advisor to Acrivon and has a deep understanding and appreciation of the breadth and novelty of our next generation precision medicine platform,” said Peter Blume-Jensen, M.D., Ph.D., chief executive officer, president, and founder of Acrivon Therapeutics.
  • At PFM, Dr. Palani led public and private biotechnology investments, and served on the board of companies in the cell therapy and gene editing fields.
  • Prior to Cowen, Dr. Palani was in oncology drug development at Pfizer Inc. and Takeda Pharmaceuticals.
  • I am excited to join a distinguished board and support the full realization of the potential of the platform applied to the company’s current pipeline and beyond.”

A.I. Supercomputer Market Projected To Reach $3.3 Billion By 2028 with Significant Growth Expected

Retrieved on: 
Monday, March 4, 2024

A report from MarketsAndMarkets said that the AI supercomputer market is projected to grow from USD $1.2 billion in 2023 and is expected to reach USD $3.3 billion by 2028, growing at a CAGR of 22.0% from 2023 to 2028.

Key Points: 
  • A report from MarketsAndMarkets said that the AI supercomputer market is projected to grow from USD $1.2 billion in 2023 and is expected to reach USD $3.3 billion by 2028, growing at a CAGR of 22.0% from 2023 to 2028.
  • The report said: “The Government segment in the AI supercomputer market for application is expected to hold the largest market size during the forecast period in the AI supercomputer market.
  • Moreover, AI supercomputers are also being used to coordinate disaster relief efforts and provide assistance to victims of disasters.
  • AI supercomputers process vast datasets in real time, providing valuable insights into customer behavior, market trends, and operational efficiency.

Shattuck Labs Announces Appointment of Clay Siegall, Ph.D., and Kate Sasser, Ph.D., to its Board of Directors

Retrieved on: 
Monday, March 4, 2024

Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck.

Key Points: 
  • Both Dr. Siegall and Dr. Sasser are highly successful executives and scientific pioneers who bring valuable industry experience to Shattuck.
  • “It is a pleasure to welcome Clay and Kate, esteemed industry leaders, to our Board of Directors,” said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • Following the next clinical updates expected mid-year, we anticipate continued expansion of and future pivotal studies for SL-172154 in multiple indications.
  • Dr. Sasser holds a Ph.D. in Integrated Biomedical Sciences from the Ohio State University as well as a B.S.